XTL Biopharmaceuticals Ltd.
XTLB | NASDAQ
$2.38
-$0.02 (-0.83%)
At close: Sep 21, 2026, 4:00 PM ET
$2.22
-$0.16 (-6.72%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Company Profile
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
Key Executives
| Name | Position |
|---|---|
| Noam Band | Chief Executive Officer & Director |
| Segal Niv | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 05, 2026 | 6-K | Filing |
| Jul 21, 2026 | 6-K | Filing |
| Jun 30, 2026 | 20-F | Filing |
| Jun 30, 2026 | 6-K | Filing |
| Jun 29, 2026 | 6-K | Filing |
| Jun 23, 2026 | 6-K | Filing |
| May 22, 2026 | 6-K | Filing |
| May 15, 2026 | 6-K | Filing |
| May 07, 2026 | 6-K | Filing |
| Apr 30, 2026 | NT 20-F | Filing |
XTL Biopharmaceuticals Ltd.
| Country | Israel |
| IPO Date | Aug 31, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Noam Band |
Contact Details
85 Medinat Hayehudim St. Herzliya,
TA 4676670 Israel
Stock Details
| Ticker Symbol | XTLB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001023549 |
| CUSIP Number | 98386D406 |
| ISIN Number | US98386D4060 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove XTLB